600267:SSEZhejiang Hisun Pharmaceutical Co., Ltd. Class A Analysis
Data as of 2026-08-28 - not real-time
CN¥12.25
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Zhejiang Hisun Pharmaceutical Co., Ltd. is priced at ¥12.25 and its moving averages line up in bullish order, the shorter sitting above the longer. The last 30 days have gained 8.2%. RSI sits at 45.6, which reads as neutral, and MACD momentum is bearish. Watch ¥11.40 as support and ¥15.00 as the nearer resistance level.
On valuation the read is fair — earnings multiple of 16.3 versus a 30.6 sector average, below the peer group. Sell-side targets cluster 32.2% below the current quote. Revenue is contracting at 20.4% on a 9.0% profit margin. The 1.70% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 6 — elevated. With 30-day volatility of 65.4%, a beta of 0.47 and a maximum drawdown of 19.7%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
This one splits by horizon — buy in the near term, hold further out, at 3/10 long-term conviction.
On valuation the read is fair — earnings multiple of 16.3 versus a 30.6 sector average, below the peer group. Sell-side targets cluster 32.2% below the current quote. Revenue is contracting at 20.4% on a 9.0% profit margin. The 1.70% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 6 — elevated. With 30-day volatility of 65.4%, a beta of 0.47 and a maximum drawdown of 19.7%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
This one splits by horizon — buy in the near term, hold further out, at 3/10 long-term conviction.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 10.87
- MACD momentum is negative
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 16.3 versus sector average of 30.6
- Trading above the 200-day average of 10.87
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 16.3 versus sector average of 30.6
- Analyst targets imply -32.2% versus the current price
- Revenue contracting at -20.4%
Key Metrics & Analysis
Financial Health
Revenue Growth-20.40%
Profit Margin8.98%
P/E Ratio16.3
ROE9.91%
ROA5.12%
Debt/Equity19.18
P/B Ratio1.6
Op. Cash FlowCN¥1.7B
Free Cash FlowCN¥1.8B
Industry P/E30.6
Technical Analysis
TrendBullish
RSI45.6
SupportCN¥11.40
ResistanceCN¥15.00
MA 20CN¥13.07
MA 50CN¥11.89
MA 200CN¥10.87
MACDBearish
VolumeDecreasing
Fear & Greed Index95.52
Valuation
Fair ValueCN¥18.77
Target PriceCN¥8.30
Upside/Downside-32.24%
GradeFair
TypeBlend
Dividend Yield1.70%
Risk Assessment
Beta0.47
Volatility65.40%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.